CN Patent

CN114249695A — 一种奥拉帕利的新晶型、制备方法及用途

Assigned to Qilu Pharmaceutical Co Ltd · Expires 2022-03-29 · 4y expired

What this patent protects

本发明属于医药化工技术领域，具体涉及一种奥拉帕利的新晶型Q及其制备方法，以及该晶型在制备药物中的用途。该晶型具有纯度高、稳定性好、易于制备、安全性好的优点，更适于存放和使用，能更好的应用于奥拉帕利原料药及制剂的制备。

USPTO Abstract

本发明属于医药化工技术领域，具体涉及一种奥拉帕利的新晶型Q及其制备方法，以及该晶型在制备药物中的用途。该晶型具有纯度高、稳定性好、易于制备、安全性好的优点，更适于存放和使用，能更好的应用于奥拉帕利原料药及制剂的制备。

Drugs covered by this patent

Patent Metadata

Patent number
CN114249695A
Jurisdiction
CN
Classification
—
Expires
2022-03-29
Drug substance claim
No
Drug product claim
No
Assignee
Qilu Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.